A COVID-19 vaccine being developed by Oxford University and drug company AstraZeneca has shown promising immune response in an early-stage human trial.
A COVID19 vaccine being developed by Oxford University with the pharmaceutical company AstraZeneca has shown promising results in early human testing. In results published in the Lancet Medical Journal, researchers said the vaccine showed a promising immune response producing antibodies and killer T-cells to combat the infection that lasted at least two months. The Head of Department at the National Institute for Communicable Diseases, NICD Prof Adrian Puren explains what this means
For more news, visit sabcnews.com and also #SABCNews, #Coronavirus, #COVID19, COVID-19 News on Social Media.
